2023 ASHP Midyear Clincial Meeting & Exhibition | December 3 – 7 | Anaheim, CA Participate in a hands-on demonstration, and learn for yourself how
– Key injectable currently on the U.S. FDA shortage list – Received Competitive Generic Therapy approval designation BRIDGEWATER, N.J.–(BUSINESS WIRE)– Amneal Pharmaceuticals, Inc. (NYSE: AMRX)
– Key ADHD medicine on the U.S. FDA shortage product list – Represents another high-value product approval for Amneal BRIDGEWATER, N.J.–(BUSINESS WIRE)— Amneal Pharmaceuticals, Inc.
– Adds first ready-to-use presentation of key injectable for treating non-squamous non-small cell
Gather with other pharmacy professionals and visit the exhibit hall at the ASHP Summer Meetings & Exhibition, and learn how these companies and their products
BRIDGEWATER, N.J.–(BUSINESS WIRE)– Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of FYLNETRA™ (pegfilgrastim-pbbk), a biosimilar referencing Neulasta® in
Product & Service Providers in: CLEANROOMS, ISOLATORS, HOODS, AND GLOVEBOXES GPO SUPPLIES PHARMACEUTICAL MANUFACTURERS As Seen In: View Amneal Pharmaceuticals’ Ad:
Available when you need them most Multi-source Injectable Products from Amneal Our ever-expanding portfolio includes corticosteroids and complex injectables that you can count on. At
Available when you need them most Multi-source Injectable Products from Amneal Our ever-expanding portfolio includes corticosteroids and complex injectables that you can count on. At
Peruse the groundbreaking Exhibit Hall, and learn for yourself how these innovative companies and their products are helping to define what is important to your
Stay informed on pharmacy supply chain news, market trends, and product releases by subscribing to RXinsider’s emails, newsletters, and publications. If building awareness with pharmacy management is part of your marketing strategy, consider advertising with RXinsider.
